(Q83372855)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

main subject

phase I clinical trial

1 reference

Caio M Rocha-Lima

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Soley Bayraktar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Jessica Macintyre

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Luis Raez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Aurea M Flores

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Annapoorna Ferrell

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Eric H Rubin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Elizabeth A Poplin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Antoinette R Tan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Antonio Lucarelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Naseem Zojwalla

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

31 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

4262-4270

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Cytotoxic peptides from the marine sponge Cymbastela sp.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Caspases: intracellular signaling by proteolysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Caspases: enemies within

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Effect of p53 status on tumor response to antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Deoxycholate induces DNA damage and apoptosis in human colon epithelial cells expressing either mutant or wild-type p53.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

New drug development in the United States from 1963 to 1999

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Risks in new drug development: approval success rates for investigational drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27428

7 January 2021

Identifiers

DOI

10.1002/CNCR.27428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22294459%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference